# Benchmarking EGF signaling pathway inference using phosphoproteomics and kinase-substrate interactions

**Authors:** Martin Garrido-Rodriguez, Clement Potel, Mira Lea Burtscher, Isabelle Becher, Pablo Rodriguez-Mier, Sophia Müller-Dott, Mikhail M. Savitski, Julio Saez-Rodriguez

PMC · DOI: 10.1038/s41467-026-69332-0 · Nature Communications · 2026-02-26

## TL;DR

This paper benchmarks how well large-scale data can reconstruct classic signaling pathways, focusing on EGF using phosphoproteomics and kinase-substrate interactions.

## Contribution

The study provides the most comprehensive characterization of the EGF response using phosphoproteomics and compares inferred pathways to ground truth sets.

## Key findings

- Literature-curated networks recover the most ground-truth interactions.
- Up to 90% of interactions are missing from current ground truth sets.
- Network propagation methods offer modest improvements in pathway recovery.

## Abstract

Signaling pathways are useful models for interpreting molecular data, but their coverage has long been constrained by classic biochemistry methods. The growing corpus of kinase-substrate interactions, coupled to phosphoproteomics improvements, pave the way to revisit classic signaling pathways. In this study, we explore context-specific signaling pathway inference from phosphoproteomics and kinase-substrate networks. Focusing on epidermal growth factor (EGF), we conduct a meta-analysis and generate three datasets representing the most comprehensive characterization of the EGF response to date. We infer kinase-kinase pathways and compare them to different ground truth sets. Literature-curated networks consistently yield the highest recovery of ground-truth interactions, with modest gains from network propagation methods. Up to 90% of interactions are absent from current ground truth sets, indicating many unexplored interactions supported by data and knowledge. Our results demonstrate the limitations of traditional views on signaling pathways and point to opportunities for generating better mechanistic hypotheses.

To what extent can large-scale approaches accurately reconstruct classic signaling pathways? Here, authors revisit the EGF pathway using phosphoproteomics and kinase-substrate interactions

## Linked entities

- **Proteins:** EGF (epidermal growth factor)

## Full-text entities

- **Genes:** MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595] {aka ERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A, P44ERK1}, PRKACG (protein kinase cAMP-activated catalytic subunit gamma) [NCBI Gene 5568] {aka BDPLT19, KAPG, PKACg}, PRKACB (protein kinase cAMP-activated catalytic subunit beta) [NCBI Gene 5567] {aka CAFD2, PKA C-beta, PKACB}, RAF1 (Raf-1 proto-oncogene, serine/threonine kinase) [NCBI Gene 5894] {aka CMD1NN, CRAF, NS5, Raf-1, c-Raf}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 6198] {aka PS6K, S6K, S6K-beta-1, S6K1, STK14A, p70 S6KA}, LCK (LCK proto-oncogene, Src family tyrosine kinase) [NCBI Gene 3932] {aka IMD22, LSK, YT16, p56lck, pp58lck}, PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159] {aka CD140B, IBGC4, IMF1, JTK12, KOGS, OPDKD}, AKT2 (AKT serine/threonine kinase 2) [NCBI Gene 208] {aka HIHGHH, PKBB, PKBBETA, PRKBB, RAC-BETA}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, AKT3 (AKT serine/threonine kinase 3) [NCBI Gene 10000] {aka MPPH, MPPH2, PKB-GAMMA, PKBG, PRKBG, RAC-PK-gamma}, PRKG1 (protein kinase cGMP-dependent 1) [NCBI Gene 5592] {aka AAT8, PKG, PKG1, PRKG1B, PRKGR1B, cGK}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, MAPK7 (mitogen-activated protein kinase 7) [NCBI Gene 5598] {aka BMK1, ERK4, ERK5, PRKM7}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, PRKACA (protein kinase cAMP-activated catalytic subunit alpha) [NCBI Gene 5566] {aka CAFD1, PKACA, PPNAD4}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}, PRKCD (protein kinase C delta) [NCBI Gene 5580] {aka ALPS3, CVID9, MAY1, PKCD, nPKC-delta}, SARDH (sarcosine dehydrogenase) [NCBI Gene 1757] {aka BPR-2, DMGDHL1, SAR, SARD, SDH}, GAB1 (GRB2 associated binding protein 1) [NCBI Gene 2549] {aka DFNB26}, FYN (FYN proto-oncogene, Src family tyrosine kinase) [NCBI Gene 2534] {aka SLK, SYN, p59-FYN}, RPS6KA5 (ribosomal protein S6 kinase A5) [NCBI Gene 9252] {aka MSK1, MSPK1, RLPK}, MAPK13 (mitogen-activated protein kinase 13) [NCBI Gene 5603] {aka MAPK 13, MAPK-13, PRKM13, SAPK4, p38delta}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}
- **Diseases:** glioblastoma (MESH:D005909), breast and lung cancer (MESH:D001943), autoimmune diseases (MESH:D001327), cancer (MESH:D009369), melanoma (MESH:D008545), neurodegenerative disorders (MESH:D019636)
- **Chemicals:** PVDF (MESH:C024865), tryptophan (MESH:D014364), PBS (MESH:D007854), Lysine (MESH:D008239), DMSO (MESH:D004121), glucose (MESH:D005947), L-glutamine (MESH:D005973), citric acid (MESH:D019343), CO2 (MESH:D002245), cysteine (MESH:D003545), hydroxylamine (MESH:D019811), TFA (MESH:D014269), chloroacetamide (MESH:C013874), Phosphopeptide (MESH:D010748), DMEM (-), N-lauroylsarcosine (MESH:C025231), 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (MESH:D006531), diethylamine (MESH:C034281), isoamyl alcohol (MESH:C029683), NaOH (MESH:D012972), ethanol (MESH:D000431), water (MESH:D014867), tyrosines (MESH:D014443), nitrogen (MESH:D009584), TPCK (MESH:D014108), acetonitrile (MESH:C032159), methionine (MESH:D008715), formic acid (MESH:C030544), TCEP (MESH:C080938)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mycoplasma (genus) [taxon 2093]
- **Cell lines:** HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), 293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), Expi293F — Homo sapiens (Human), Transformed cell line (CVCL_D615), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), HEK293F — Homo sapiens (Human), Transformed cell line (CVCL_6642)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12949236/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12949236/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12949236/full.md

---
Source: https://tomesphere.com/paper/PMC12949236